Compare Incyte Corporation (INCY) vs Palo Alto Networks Inc (PANW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Palo Alto Networks Inc — how do they compare? Incyte Corporation trades at $113.37 (market cap $22.85B), while Palo Alto Networks Inc trades at $417.47 (market cap $331.76B). The key difference: Palo Alto Networks Inc is far larger — about 14.5× Incyte Corporation's market cap, and Palo Alto Networks Inc is trading nearer its 52-week high, Incyte Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Palo Alto Networks Inc for 82 Days on average.
| INCY | PANW | |
|---|---|---|
Market Cap | $22.85B | $331.76B |
Volume | 1,927,029 | 3,886,927 |
Sector | Health | Technology |
52-Week High | $129.93 | $419.91 |
52-Week Low | $83.80 | $141.67 |
Typical Hold Time | 33 Days | 82 Days |
Enterprise Value | $18.35B | $331.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $113.61, up 0.15% on the day, with a mixed technical signal leaning bearish. The company reported strong 2025 results with revenue of $5.14B and net income of $1.29B, and recent earnings beats in Q1 and Q2 2026. Key developments include FDA approval for Atebrioz and a strategic focus on post-JAKAFI growth targeting $4B in non-JAKAFI sales by 2029.
The outlook is cautiously optimistic, supported by robust profitability and pipeline progress, but tempered by near-term earnings pressure and technical weakness. Risks include JAKAFI's patent expiration after 2029 and competitive threats. Analysts maintain a Buy consensus with a $132.43 price target, implying significant upside from current levels.
Palo Alto Networks (PANW) trades at $414.27, up 2.19% today and near its 52-week high, with strong technical momentum and bullish moving average signals. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Revenue growth remains robust, climbing from $5.5B in 2022 to $9.2B in 2025, though net income margins have compressed from 32.1% to 2.67% as the company invests heavily in AI-driven security platforms.
The outlook remains positive given strong AI cybersecurity demand and platformization strategy, but premium valuations (P/E 1,013.93, P/S 26.99) and rising costs present risks. Analyst consensus is strongly bullish with 72% buy ratings and a $398.70 price target, though current price exceeds the target, suggesting near-term caution may be warranted despite long-term growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Palo Alto Networks Inc
Palo Alto Networks is a pure-play cybersecurity vendor that sells security appliances, subscriptions, and support into enterprises, government entities, and service providers. The company's product portfolio includes firewall appliances, virtual firewalls, endpoint protection, cloud security, and cybersecurity analytics. The Santa Clara, California, firm was established in 2005 and sells its products worldwide.
Read more on PANW →
